Näytetään tulokset 1 - 10 / 1078
tulosta / sivu
Mitä julkaisutietoja palvelu sisältää?
Julkaisun nimi
Tekijät
Julkaisukanava
Vuosi
 Julkaisujen tiedon ikoni

MEK and PI3K inhibition in solid tumors : rationale and evidence to date

Vertaisarvioitu
Avoin saatavuus
DOI
10.1177/1758834015571111
Jokinen, E.; Koivunen, J. P.
Therapeutic advances in medical oncology2015 Julkaisujen tiedon ikoni

A RAS-Independent Biomarker Panel to Reliably Predict Response to MEK Inhibition in Colorectal Cancer

Vertaisarvioitu
Avoin saatavuus
DOI
10.3390/cancers14133252
Pfohl, Ulrike; Loskutov, Jürgen; Bashir, Sanum; Kühn, Ralf; Herter, Patrick; Templin, Markus; Mamlou...
Cancers2022 Julkaisujen tiedon ikoni

Impact of MEK Inhibition on Childhood RASopathy-Associated Hypertrophic Cardiomyopathy

Vertaisarvioitu
Avoin saatavuus
DOI
10.1016/j.jacbts.2024.10.002
Wolf, Cordula M.; Zenker, Martin; Boleti, Olga; Norrish, Gabrielle; Russell, Mark; Meisner, Joshua K...
JACC : Basic to translational science2025 Julkaisujen tiedon ikoni

Alternative dosing of dual P13K and MEK inhibition in cancer therapy

Vertaisarvioitu
Avoin saatavuus
DOI
10.1186/1471-2407-12-612
Jokinen, Elina; Laurila, Niina; Koivunen, Jussi P
Bmc cancer2012 Julkaisujen tiedon ikoni

Alternative dosing of dual PI3K and MEK inhibition in cancer therapy

Vertaisarvioitu
Jokinen E; Laurila N; Koivunen JP
Bmc Cancer [online: Http://www.Biomedcentral.Com/bmccancer/]2012 Julkaisujen tiedon ikoni

Bcl-xl and Mcl-1 are the major determinants of the apoptotic response to dual PI3K and MEK blockage

Vertaisarvioitu
DOI
10.3892/ijo.2015.3071
Jokinen, Elina; Koivunen, Jussi P.
International journal of oncology2015 Julkaisujen tiedon ikoni

MEK and PI3K inhibition in solid tumors: rationale and evidence to date

Vertaisarvioitu
Jokinen E; Koivunen JP
Therapeutic Advances in Medical Oncology2015 Julkaisujen tiedon ikoni

Simulating BRAFV600E-MEK-ERK signalling dynamics in response to vertical inhibition treatment strategies

Vertaisarvioitu
Avoin saatavuus
DOI
10.1038/s41540-024-00379-9
De Carli, Alice; Kapelyukh, Yury; Kursawe, Jochen; Chaplain, Mark A.J.; Wolf, C. Roland; Hamis, Sara...
npj Systems Biology and Applications2024 Julkaisujen tiedon ikoni

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells

Vertaisarvioitu
DOI
10.1126/scitranslmed.aaq1093
Kauko, Otto; O'Connor, Caitlin M.; Kulesskiy, Evgeny; Sangodkar, Jaya; Aakula, Anna; Izadmehr, Sudeh...
Science translational medicine2018 Julkaisujen tiedon ikoni

Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers

Vertaisarvioitu
Avoin saatavuus
DOI
10.1016/j.celrep.2020.107764
Ozkan-Dagliyan, Irem; Diehl, J. Nathaniel; George, Samuel D.; Schaefer, Antje; Papke, Bjoern; Klotz-...
Cell Reports2020

MEK and PI3K inhibition in solid tumors : rationale and evidence to date

Vertaisarvioitu
Avoin saatavuus
DOI
10.1177/1758834015571111
2015

A RAS-Independent Biomarker Panel to Reliably Predict Response to MEK Inhibition in Colorectal Cancer

Vertaisarvioitu
Avoin saatavuus
DOI
10.3390/cancers14133252
2022

Impact of MEK Inhibition on Childhood RASopathy-Associated Hypertrophic Cardiomyopathy

Vertaisarvioitu
Avoin saatavuus
DOI
10.1016/j.jacbts.2024.10.002
2025

Alternative dosing of dual P13K and MEK inhibition in cancer therapy

Vertaisarvioitu
Avoin saatavuus
DOI
10.1186/1471-2407-12-612
2012

Alternative dosing of dual PI3K and MEK inhibition in cancer therapy

Vertaisarvioitu
2012

Bcl-xl and Mcl-1 are the major determinants of the apoptotic response to dual PI3K and MEK blockage

Vertaisarvioitu
DOI
10.3892/ijo.2015.3071
2015

MEK and PI3K inhibition in solid tumors: rationale and evidence to date

Vertaisarvioitu
2015

Simulating BRAFV600E-MEK-ERK signalling dynamics in response to vertical inhibition treatment strategies

Vertaisarvioitu
Avoin saatavuus
DOI
10.1038/s41540-024-00379-9
2024

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells

Vertaisarvioitu
DOI
10.1126/scitranslmed.aaq1093
2018

Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers

Vertaisarvioitu
Avoin saatavuus
DOI
10.1016/j.celrep.2020.107764
2020